Shares of Praxis Precision Medicines, Inc. more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive data from a pair of late-stage clinical trials. #biopharma https://lnkd.in/e6VN8Ab7
BioPharma Dive
Online Audio and Video Media
Washington, District of Columbia 16,221 followers
We provide business journalism and in-depth insight into the most impactful news and trends shaping biotech and pharma
About us
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 13+ million decision-makers in the most competitive industries.
- Website
-
http://www.biopharmadive.com
External link for BioPharma Dive
- Industry
- Online Audio and Video Media
- Company size
- 201-500 employees
- Headquarters
- Washington, District of Columbia
Updates
-
A #GeneTherapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine were among the first beneficiaries of a pilot program initiated in June. #pharma https://lnkd.in/eAyEiww8
-
The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to later-line settings for the persistent blood #cancer. #pharma https://lnkd.in/gGRmuB-C
-
Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive data from a pair of late-stage clinical trials. #biopharma https://lnkd.in/gc9YGEiW
-
Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to activate dormant hair follicle stem cells. #biotech https://lnkd.in/gcUrmv93
-
Some Wall Street analysts have questioned #orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials. #pharma https://lnkd.in/g5RUAhyj
-
Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a dozen children with a rare, genetic form of deafness. #biopharma https://lnkd.in/gTS6v4nh
-
Among the largest private #biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China. https://lnkd.in/gF65avqk
-
The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other #therapies for chronic skin hives. #biotech https://lnkd.in/gVnMXpV3
-
The acquisition of the well-funded #startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body. #biopharma https://lnkd.in/gGsbvxMi